Parlux
This article was originally published in The Rose Sheet
Executive Summary
Preliminary year-end revenues for the company are projected to reach $183 mil., an 82% increase over the prior fiscal year, according to Parlux. Firm attributes results to growth of Paris Hilton brand, the launch of GUESS! scents and performance of Perry Ellis fragrances. Upcoming introduction of Paris Hilton cosmetics will contribute to increased FY 2007 revenues, which are anticipated to be $270 mil.-$280 mil., company notes. Firm will issue final results by June 14...
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.